BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

379 related articles for article (PubMed ID: 19880498)

  • 1. Gene expression classifiers for relapse-free survival and minimal residual disease improve risk classification and outcome prediction in pediatric B-precursor acute lymphoblastic leukemia.
    Kang H; Chen IM; Wilson CS; Bedrick EJ; Harvey RC; Atlas SR; Devidas M; Mullighan CG; Wang X; Murphy M; Ar K; Wharton W; Borowitz MJ; Bowman WP; Bhojwani D; Carroll WL; Camitta BM; Reaman GH; Smith MA; Downing JR; Hunger SP; Willman CL
    Blood; 2010 Feb; 115(7):1394-405. PubMed ID: 19880498
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Effects of minimal residual disease level on day 33 of remission induction and IKZF1 genotype on the survival of children with B-lineage acute lymphoblastic leukemia].
    Kuang WY; Zheng MC; Li WL; Yang HX; Zhang BS; Wu P
    Zhongguo Dang Dai Er Ke Za Zhi; 2018 Jul; 20(7):538-542. PubMed ID: 30022754
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The clinical impact of IKZF1 deletions in paediatric B-cell precursor acute lymphoblastic leukaemia is independent of minimal residual disease stratification in Nordic Society for Paediatric Haematology and Oncology treatment protocols used between 1992 and 2013.
    Olsson L; Ivanov Öfverholm I; Norén-Nyström U; Zachariadis V; Nordlund J; Sjögren H; Golovleva I; Nordgren A; Paulsson K; Heyman M; Barbany G; Johansson B
    Br J Haematol; 2015 Sep; 170(6):847-58. PubMed ID: 26018335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcome modeling with CRLF2, IKZF1, JAK, and minimal residual disease in pediatric acute lymphoblastic leukemia: a Children's Oncology Group study.
    Chen IM; Harvey RC; Mullighan CG; Gastier-Foster J; Wharton W; Kang H; Borowitz MJ; Camitta BM; Carroll AJ; Devidas M; Pullen DJ; Payne-Turner D; Tasian SK; Reshmi S; Cottrell CE; Reaman GH; Bowman WP; Carroll WL; Loh ML; Winick NJ; Hunger SP; Willman CL
    Blood; 2012 Apr; 119(15):3512-22. PubMed ID: 22368272
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A risk score including microdeletions improves relapse prediction for standard and medium risk precursor B-cell acute lymphoblastic leukaemia in children.
    Sutton R; Venn NC; Law T; Boer JM; Trahair TN; Ng A; Den Boer ML; Dissanayake A; Giles JE; Dalzell P; Mayoh C; Barbaric D; Revesz T; Alvaro F; Pieters R; Haber M; Norris MD; Schrappe M; Dalla Pozza L; Marshall GM
    Br J Haematol; 2018 Feb; 180(4):550-562. PubMed ID: 29194562
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IKZF1
    Stanulla M; Dagdan E; Zaliova M; Möricke A; Palmi C; Cazzaniga G; Eckert C; Te Kronnie G; Bourquin JP; Bornhauser B; Koehler R; Bartram CR; Ludwig WD; Bleckmann K; Groeneveld-Krentz S; Schewe D; Junk SV; Hinze L; Klein N; Kratz CP; Biondi A; Borkhardt A; Kulozik A; Muckenthaler MU; Basso G; Valsecchi MG; Izraeli S; Petersen BS; Franke A; Dörge P; Steinemann D; Haas OA; Panzer-Grümayer R; Cavé H; Houlston RS; Cario G; Schrappe M; Zimmermann M; ;
    J Clin Oncol; 2018 Apr; 36(12):1240-1249. PubMed ID: 29498923
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ikaros (IKZF1) alterations and minimal residual disease at day 15 assessed by flow cytometry predict prognosis of childhood BCR/ABL-negative acute lymphoblastic leukemia.
    Volejnikova J; Mejstrikova E; Dörge P; Meissner B; Zimmermannova O; Svojgr K; Stanulla M; Cario G; Schrappe M; Stary J; Hrusak O; Trka J; Fronkova E
    Pediatr Blood Cancer; 2013 Mar; 60(3):420-7. PubMed ID: 22997141
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrated use of minimal residual disease classification and IKZF1 alteration status accurately predicts 79% of relapses in pediatric acute lymphoblastic leukemia.
    Waanders E; van der Velden VH; van der Schoot CE; van Leeuwen FN; van Reijmersdal SV; de Haas V; Veerman AJ; van Kessel AG; Hoogerbrugge PM; Kuiper RP; van Dongen JJ
    Leukemia; 2011 Feb; 25(2):254-8. PubMed ID: 21102428
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor suppressors BTG1 and IKZF1 cooperate during mouse leukemia development and increase relapse risk in B-cell precursor acute lymphoblastic leukemia patients.
    Scheijen B; Boer JM; Marke R; Tijchon E; van Ingen Schenau D; Waanders E; van Emst L; van der Meer LT; Pieters R; Escherich G; Horstmann MA; Sonneveld E; Venn N; Sutton R; Dalla-Pozza L; Kuiper RP; Hoogerbrugge PM; den Boer ML; van Leeuwen FN
    Haematologica; 2017 Mar; 102(3):541-551. PubMed ID: 27979924
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Refining risk stratification in paediatric B-acute lymphoblastic leukaemia: Combining IKZF1
    Liu HC; Huang YJ; Jaing TH; Wu KH; Chen SH; Wang SC; Yeh TC; Hsiao CC; Chang TK; Yen HJ; Huang FL; Lin PC; Hou JY; Sheen JM; Liao YM; Chang TY; Chen YC; Chiou SS; Yang CP; Pui CH; Liang DC; Shih LY
    Br J Haematol; 2024 Apr; 204(4):1344-1353. PubMed ID: 38479427
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Breakpoint-specific multiplex polymerase chain reaction allows the detection of IKZF1 intragenic deletions and minimal residual disease monitoring in B-cell precursor acute lymphoblastic leukemia.
    Caye A; Beldjord K; Mass-Malo K; Drunat S; Soulier J; Gandemer V; Baruchel A; Bertrand Y; Cavé H; Clappier E
    Haematologica; 2013 Apr; 98(4):597-601. PubMed ID: 23065506
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia.
    Harvey RC; Mullighan CG; Chen IM; Wharton W; Mikhail FM; Carroll AJ; Kang H; Liu W; Dobbin KK; Smith MA; Carroll WL; Devidas M; Bowman WP; Camitta BM; Reaman GH; Hunger SP; Downing JR; Willman CL
    Blood; 2010 Jul; 115(26):5312-21. PubMed ID: 20139093
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study.
    Borowitz MJ; Devidas M; Hunger SP; Bowman WP; Carroll AJ; Carroll WL; Linda S; Martin PL; Pullen DJ; Viswanatha D; Willman CL; Winick N; Camitta BM;
    Blood; 2008 Jun; 111(12):5477-85. PubMed ID: 18388178
    [TBL] [Abstract][Full Text] [Related]  

  • 14. What is the relevance of Ikaros gene deletions as a prognostic marker in pediatric Philadelphia-negative B-cell precursor acute lymphoblastic leukemia?
    Palmi C; Valsecchi MG; Longinotti G; Silvestri D; Carrino V; Conter V; Basso G; Biondi A; Kronnie GT; Cazzaniga G
    Haematologica; 2013 Aug; 98(8):1226-31. PubMed ID: 23585525
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The value of minimal residual disease and IKZF1 deletion for predicting prognosis in adult patients with B-cell acute lymphoblastic leukemia].
    Deng SY; Ou JW; Huang ZC; Chen JJ; Cai ZH; Liu QF; Zhou HS
    Zhonghua Xue Ye Xue Za Zhi; 2024 Mar; 45(3):257-263. PubMed ID: 38716597
    [No Abstract]   [Full Text] [Related]  

  • 16. Prognostic value of genetic alterations in children with first bone marrow relapse of childhood B-cell precursor acute lymphoblastic leukemia.
    Krentz S; Hof J; Mendioroz A; Vaggopoulou R; Dörge P; Lottaz C; Engelmann JC; Groeneveld TW; Körner G; Seeger K; Hagemeier C; Henze G; Eckert C; von Stackelberg A; Kirschner-Schwabe R
    Leukemia; 2013 Feb; 27(2):295-304. PubMed ID: 22699455
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IKZF1 deletions predict relapse in uniformly treated pediatric precursor B-ALL.
    Kuiper RP; Waanders E; van der Velden VH; van Reijmersdal SV; Venkatachalam R; Scheijen B; Sonneveld E; van Dongen JJ; Veerman AJ; van Leeuwen FN; van Kessel AG; Hoogerbrugge PM
    Leukemia; 2010 Jul; 24(7):1258-64. PubMed ID: 20445578
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of minimal residual disease identifies differences in treatment response between T-ALL and precursor B-ALL.
    Willemse MJ; Seriu T; Hettinger K; d'Aniello E; Hop WC; Panzer-Grümayer ER; Biondi A; Schrappe M; Kamps WA; Masera G; Gadner H; Riehm H; Bartram CR; van Dongen JJ
    Blood; 2002 Jun; 99(12):4386-93. PubMed ID: 12036866
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of residual disease in pediatric B-cell precursor acute lymphoblastic leukemia by comparative phenotype mapping: method and significance.
    Dworzak MN; Fritsch G; Panzer-Grümayer ER; Mann G; Gadner H
    Leuk Lymphoma; 2000 Jul; 38(3-4):295-308. PubMed ID: 10830736
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Refining risk classification in childhood B acute lymphoblastic leukemia: results of DFCI ALL Consortium Protocol 05-001.
    Vrooman LM; Blonquist TM; Harris MH; Stevenson KE; Place AE; Hunt SK; O'Brien JE; Asselin BL; Athale UH; Clavell LA; Cole PD; Kelly KM; Laverdiere C; Leclerc JM; Michon B; Schorin MA; Sulis ML; Welch JJG; Neuberg DS; Sallan SE; Silverman LB
    Blood Adv; 2018 Jun; 2(12):1449-1458. PubMed ID: 29941458
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.